AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model

MLA

Premal H. Thaker, et al. “AVB500, a Receptor Tyrosine Kinase AXL Inhibitor, Has Improved Therapeutic Efficacy in Combination with Bevacizumab Compared to Bevacizumab Alone in Uterine Serous Cancer Mouse Model.” Gynecologic Oncology, vol. 159, Oct. 2020, p. 77. EBSCOhost, https://doi.org/10.1016/j.ygyno.2020.06.162.

APA

Premal H. Thaker, L.M. Kuroki, P. Cannon, Hollie Noia, Joan Tankou, Alyssa Oplt, C.K. McCourt, David G. Mutch, Mary M. Mullen, A.R. Hagemann, M.A. Powell, Michael D. Toboni, & K.C. Fuh. (2020). AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model. Gynecologic Oncology, 159, 77. https://doi.org/10.1016/j.ygyno.2020.06.162

Chicago

Premal H. Thaker, L.M. Kuroki, P. Cannon, Hollie Noia, Joan Tankou, Alyssa Oplt, C.K. McCourt, et al. 2020. “AVB500, a Receptor Tyrosine Kinase AXL Inhibitor, Has Improved Therapeutic Efficacy in Combination with Bevacizumab Compared to Bevacizumab Alone in Uterine Serous Cancer Mouse Model.” Gynecologic Oncology 159 (October): 77. doi:10.1016/j.ygyno.2020.06.162.